Brivaracetam

Specifications

357336-20-0CAS Number

801-184-2EC Number

(2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamideIUPAC Name

C11H20N2O2Chemical Formula

212.29 g/molMolecular Weight

Brivaracetam; 357336-20-0; Briviact; UCB 34714; UCB-34714; UCB34714; (2s)-2-[(4r)-2-oxo-4-propylpyrrolidin-1-yl]butanamide; U863JGG2IA; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-4-propyl-, (alphaS,4R)-; CHEBI:133013; DTXSID00905081; (2S)-2-((4R)-2-Oxo-4-propylpyrrolidin-1-yl)butanamide; brivaracetamum; RefChem:57048; N03AX23; DTXCID601334183; (2S)-2-((4R)-2-OXO-4-PROPYLTETRAHYDRO-1H-PYRROL-1-YL) BUTANAMIDE; 2-(2-oxo-4-propylpyrrolidin-1-yl)butanamide; MFCD25976668; (S)-2-((R)-2-Oxo-4-propylpyrrolidin-1-yl)butanamide; Rikelta; Brivaracetam [USAN:INN]; UNII-U863JGG2IA; Brivaracetam?; (2S)-2-[(4R)-2-oxidanylidene-4-propyl-pyrrolidin-1-yl]butanamide; compound 83alpha; (R)-Atomoxetine; Briviact (TN); 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-4-propyl-, (alphaS,4R)-; (alphaS,4R)-alpha-Ethyl-2-oxo-4-propyl-1-pyrrolidineacetamide; Brivaracetam; Briviact; UCB 34714; BRIVARACETAM [MI]; BRIVARACETAM [INN]; BRIVARACETAM [JAN]; BRIVARACETAM [USAN]; Brivaracetam [EP monograph]; BRIVARACETAM [MART.]; orb363926; BRIVARACETAM [WHO-DD]; SCHEMBL122081; Brivaracetam (JAN/USAN/INN); CHEMBL607400; GTPL9041; AE5 - Anti-epileptic drugs 5; (2S)-2-[(4R)-2-oxo-4-propyl-pyrrolidin-1-yl]butanamide; DEA NO. 2710; MSYKRHVOOPPJKU-BDAKNGLRSA-N; BRIVARACETAM [ORANGE BOOK]; GLXC-27574; EX-A2748; BDBM50422531; AKOS027324306; BRIVIACT (IN ITALY: NUBRIVEO); CCG-266666; CS-3418; DB05541; BRIVIACT (IN ITALY: NUBRIVEO); NCGC00390779-02; AC-29289; AS-35277; BB161996; HY-14449; NS00068020; D08879; Q408099; BRD-K00634421-001-01-0; (2S)-2-((4R)-2-oxo-4-n-propyl-1-pyrrolidinyl)butanamide; (2S)-2-[(4R)-2-Oxo-4-propyl-1-pyrrolidinyl]butanamide; (alphaS,4R)-alpha-Ethyl-2-oxo-4-propyl-1-pyrrolidineacetamide; 1-Pyrrolidineacetamide alpha-ethyl-2-oxo-4-propyl-, (alphaS,4R)-Synonyms